60
Participants
Start Date
December 20, 2024
Primary Completion Date
July 31, 2026
Study Completion Date
January 31, 2027
radiotherapy 5 Gy × 5 fractions, once a day
5 Gy × 5 fractions, once a day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
radiotherapy 8 Gy × 5 fractions, once a day
8 Gy × 5 fractions, once a day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
radiotherapy 8 Gy × 3 fractions, once every other day
8 Gy × 3 fractions, once every other day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
radiotherapy 10 Gy× 3 fractions, once every other day
10 Gy × 3 fractions, once every other day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)
0.5 Gy twice-a-day × 2 days, on the first 2 days of the first 4 cycles of toripalimab and chemotherapy (total 8Gy)
Toripalimab
Toripalimab (240 mg IV, d1, Q3W)
chemotherapy regimen selected by the investigator
Regimens to be selected from: (1) Nab-paclitaxel (125 mg/m2 IV, days 1, 8, Q3W) (2) Gemcitabine (1000 mg/m² IV, days 1 and 8, Q3W) + carboplatin (AUC=2 IV, days 1 and 8, Q3W)
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
West China Hospital
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Sun Yat-sen University
OTHER